Immunocore Holdings plc

NASDAQ:IMCR

Biotechnology

Healthcare
$27.51 +0.63%

+$0.18 today

Market cap
$1.42B
Beta
0.75
P/E (TTM)
-77.5
EPS (TTM)
-$0.37
52W Low $27.56High $40.72

Volume 0.30M

Average 0.40M

IMCR Operating Expenses

Total costs of running the business that are not directly tied to producing goods or services sold.

Immunocore Holdings plcNASDAQ: IMCR

Operating Expenses · Q1 FY2026 · quarter ended Mar 2026

Operating expenses grows, but more slowly than its trailing trend

Q1 FY2026 operating expenses of $98.96M rose 2.4% year over year, behind the +8.6% change in trailing-twelve-month operating expenses. Sequentially, it rose 10.7% from the prior quarter. Over 3 fiscal years it compounded at +21.4% a year.

Context

  • Operating expenses amounted to 109.2% of revenue in FY2025, down 11.2 pp from a year earlier.
  • Operating expenses increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from +2.4% toward the trailing-twelve-month pace of +8.6%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$98.96M+10.7% QoQ
Last fiscal yearDec 2025
$325.09M+8.8% YoY
LTMMar 2026
$410.51M+8.6% YoY
Operating Expenses past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+2.4%——
1 year+8.8%——
3-year CAGR+21.4%——
5-year CAGR——
10-year CAGR——

Operating Expenses history

Mixed currencies · from the income statement

Latest · FY2025
325.09M USD
Year-over-year change
+8.8%

Operating Expenses vs competitors

How IMCR compares with its peers on the latest reported figures

  • Peers report in different currencies, so operating expenses is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +8.6% is the 7th highest of 11, against a peer median of +16.8%.
  • Operating expenses amounts to 106.4% of revenue for IMCR, versus a peer median of 379.3%.
IMCR Competitors
Operating Expenses for IMCR and competitors
Company Period LTM YoY 3-year CAGR% of revenue
BNTXBioNTech SELTM Jun 2026€3.77B EUR+18.8%+18.2%142.6%
RCUSArcus Biosciences, Inc.LTM Jun 2026$596M USD-0.7%+16.7%509.4%
IBRXImmunityBio, Inc.LTM Sep 2026$450.66M USD+32.9%+1.6%246.8%
IMCRImmunocore Holdings plcLTM Mar 2026$410.51M USD+8.6%+21.4%106.4%
XNCRXencor, Inc.LTM Jun 2026$261.54M USD+14.7%+83.3%249.1%
IMTXImmatics N.V.LTM Mar 2026€250M EUR+22.1%+17.2%670.3%
MGNXMacroGenics, Inc.LTM Mar 2026$173.51M USD-10.6%-12.1%110.5%
JANXJanux Therapeutics, Inc.LTM Mar 2026$168.69M USD+127.4%+30.3%780.5%
IMMPImmutep LimitedFY2025A$70.06M AUD+39.0%+29.1%1388.9%
IPHAInnate Pharma S.A.FY2025€56.21M EUR-12.4%-3.9%2016.9%
CGENCompugen Ltd.LTM Mar 2026$33.28M USD-2.6%-8.4%45.8%
Peer median (excluding IMCR) —+16.8%+17.0%379.3%

Competitors are the stored peer set for IMCR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

Mixed currencies
Metric
FY2021
Dec 2021 · GBP
FY2022
Dec 2022 · GBP
FY2023
Dec 2023 · GBP
FY2024
Dec 2024 · USD
FY2025
Dec 2025 · USD
Revenue27.04M144.23M197.39M247.98M297.57M
Cost of Revenue05.29M820.63K5.54M6.21M
Gross Profit27.04M138.94M196.57M242.44M291.36M
Gross Margin100.0%96.3%99.6%97.8%97.9%
Research & Development74.31M84.31M129.42M177.44M204.47M
Selling, General & Admin82.15M0114.35M121.17M120.62M
Operating Expenses156.46M181.71M243.77M298.77M325.09M
Depreciation & Amortization5.63M4.41M3.24M3.36M2.43M
EBITDA(123.58M)(38.35M)(40.87M)(38.5M)387.18K
EBITDA Margin-457.0%-26.6%-20.7%-15.5%0.1%
Operating Income(129.42M)(42.77M)(47.2M)(56.28M)(33.74M)
Operating Margin-478.5%-29.7%-23.9%-22.7%-11.3%
Interest Income65K3.76M14.23M25.62M16.48M
Interest Expense5.57M5.41M4.08M18.84M12.17M
Other Income / Expenses(3.92M)8.95M(982.07K)14.01M19.53M
Income Before Tax(133.34M)(33.82M)(48.19M)(42.32M)(14.21M)
Pre-Tax Margin-493.0%-23.4%-24.4%-17.1%-4.8%
Income Tax Expense111.19K9.65M(4.43M)(1.48M)12.21M
Net Income(133.45M)(43.46M)(43.75M)(40.81M)(26.42M)
Net Margin-493.4%-30.1%-22.2%-16.5%-8.9%
EPS (Basic)(3.13)(0.95)(0.89)(1.02)(0.53)
EPS (Diluted)(3.00)(0.95)(0.89)(1.02)(0.53)
Weighted Avg Shares42.49M45.71M48.89M49.99M50.35M
Weighted Avg Shares (Diluted)43.86M45.71M48.89M49.99M50.35M

Immunocore Holdings plc

NASDAQ:IMCR

Intrinsic Alpha fair value

Locked

Current Price

$27.51

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.